Information for the public
Eculizumab (also called Soliris) works well enough and is recommended as a possible treatment for people with atypical haemolytic uraemic syndrome (aHUS). It should only be used if certain conditions are in place. These include that an expert centre oversees your treatment, and that there is monitoring and research on the dose of eculizumab and when, whether and why the drug is stopped.
If you have aHUS, and your doctor thinks that eculizumab is the right treatment, you should be able to have the treatment on the NHS. Eculizumab should be available on the NHS within 3 months of the guidance being issued. Your doctor should ask you if details of your treatment can be collected.